Do analysts prefer BGM or PLYX?

Polaryx Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 301.89%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Polaryx Therapeutics is more favorable than BGM Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Polaryx Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has higher earnings and valuation, BGM or PLYX?

Polaryx Therapeutics has lower revenue, but higher earnings than BGM Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BGM Group $37.92M 0.79 -$19.94M N/A N/A Polaryx Therapeutics N/A N/A -$8.98M -$0.05 N/A

Is BGM or PLYX more profitable?

Company Net Margins Return on Equity Return on Assets BGM Group N/A N/A N/A Polaryx Therapeutics N/A N/A N/A

Do analysts prefer CPIX or BGM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, CPIX or BGM?

Cumberland Pharmaceuticals has higher earnings, but lower revenue than BGM Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cumberland Pharmaceuticals $22.30M 5.30 -$2.84M -$0.71 N/A BGM Group $37.92M 0.79 -$19.94M N/A N/A

Do analysts rate RFL or BGM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, RFL or BGM?

BGM Group has higher revenue and earnings than Rafael. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rafael $920K 111.35 -$30.52M -$0.68 N/A BGM Group $37.92M 0.79 -$19.94M N/A N/A

Is RFL or BGM more profitable?

BGM Group has a net margin of 0.00% compared to Rafael's net margin of -3,321.74%. BGM Group's return on equity of 0.00% beat Rafael's return on equity. Company Net Margins Return on Equity Return on Assets Rafael -3,321.74% -41.27% -35.32% BGM Group N/A N/A N/A

Do analysts recommend BGM or ICCC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ImmuCell 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, BGM or ICCC?

ImmuCell has lower revenue, but higher earnings than BGM Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BGM Group $37.92M 0.79 -$19.94M N/A N/A ImmuCell $27.64M 3.57 -$1.04M -$0.06 N/A

Is BGM or ICCC more profitable?

BGM Group has a net margin of 0.00% compared to ImmuCell's net margin of -1.82%. BGM Group's return on equity of 0.00% beat ImmuCell's return on equity. Company Net Margins Return on Equity Return on Assets BGM Group N/A N/A N/A ImmuCell -1.82% -1.88% -1.22%

Do analysts prefer HRTX or BGM?

Heron Therapeutics presently has a consensus target price of $2.00, suggesting a potential upside of 439.08%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Heron Therapeutics is more favorable than BGM Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heron Therapeutics 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, HRTX or BGM?

BGM Group has lower revenue, but higher earnings than Heron Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Heron Therapeutics $150.71M 0.47 -$20.19M -$0.18 N/A BGM Group $37.92M 0.79 -$19.94M N/A N/A

BGM Group (BGM) Competitors

$0.31 +0.01 (+2.53%)

As of 12:44 PM Eastern

Compare

BGM vs. PLYX, CPIX, RFL, ICCC, and HRTX

Should you buy BGM Group stock or one of its competitors? MarketBeat compares BGM Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BGM Group include Polaryx Therapeutics (PLYX), Cumberland Pharmaceuticals (CPIX), Rafael (RFL), ImmuCell (ICCC), and Heron Therapeutics (HRTX). These companies are all part of the "pharmaceuticals" industry.

How does BGM Group compare to Polaryx Therapeutics?

BGM Group (NASDAQ:BGM) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

Polaryx Therapeutics has lower revenue, but higher earnings than BGM Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BGM Group	$37.92M	0.79	-$19.94M	N/A	N/A
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.05	N/A

Company	Net Margins	Return on Equity	Return on Assets
BGM Group	N/A	N/A	N/A
Polaryx Therapeutics	N/A	N/A	N/A

In the previous week, BGM Group's average media sentiment score of 0.00 equaled Polaryx Therapeutics'average media sentiment score.

Company	Overall Sentiment
BGM Group	Neutral
Polaryx Therapeutics	Neutral

Polaryx Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 301.89%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Polaryx Therapeutics is more favorable than BGM Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Polaryx Therapeutics beats BGM Group on 4 of the 5 factors compared between the two stocks.

How does BGM Group compare to Cumberland Pharmaceuticals?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and BGM Group (NASDAQ:BGM) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BGM Group has a net margin of 0.00% compared to Cumberland Pharmaceuticals' net margin of -34.40%. BGM Group's return on equity of 0.00% beat Cumberland Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-34.40%	-26.77%	-8.97%
BGM Group	N/A	N/A	N/A

In the previous week, Cumberland Pharmaceuticals had 5 more articles in the media than BGM Group. MarketBeat recorded 5 mentions for Cumberland Pharmaceuticals and 0 mentions for BGM Group. BGM Group's average media sentiment score of 0.00 beat Cumberland Pharmaceuticals' score of -0.78 indicating that BGM Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Cumberland Pharmaceuticals	Negative
BGM Group	Neutral

Cumberland Pharmaceuticals has higher earnings, but lower revenue than BGM Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$22.30M	5.30	-$2.84M	-$0.71	N/A
BGM Group	$37.92M	0.79	-$19.94M	N/A	N/A

15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are owned by insiders. Comparatively, 58.7% of BGM Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Cumberland Pharmaceuticals has a beta of 0.08, meaning that its share price is 92% less volatile than the broader market. Comparatively, BGM Group has a beta of 1.8, meaning that its share price is 80% more volatile than the broader market.

Summary

BGM Group beats Cumberland Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does BGM Group compare to Rafael?

Rafael (NYSE:RFL) and BGM Group (NASDAQ:BGM) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

In the previous week, Rafael's average media sentiment score of 0.00 equaled BGM Group'saverage media sentiment score.

Company	Overall Sentiment
Rafael	Neutral
BGM Group	Neutral

BGM Group has a net margin of 0.00% compared to Rafael's net margin of -3,321.74%. BGM Group's return on equity of 0.00% beat Rafael's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rafael	-3,321.74%	-41.27%	-35.32%
BGM Group	N/A	N/A	N/A

BGM Group has higher revenue and earnings than Rafael.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rafael	$920K	111.35	-$30.52M	-$0.68	N/A
BGM Group	$37.92M	0.79	-$19.94M	N/A	N/A

11.3% of Rafael shares are owned by institutional investors. 32.9% of Rafael shares are owned by company insiders. Comparatively, 58.7% of BGM Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Rafael has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market. Comparatively, BGM Group has a beta of 1.8, suggesting that its stock price is 80% more volatile than the broader market.

Summary

BGM Group beats Rafael on 7 of the 9 factors compared between the two stocks.

How does BGM Group compare to ImmuCell?

BGM Group (NASDAQ:BGM) and ImmuCell (NASDAQ:ICCC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

ImmuCell has lower revenue, but higher earnings than BGM Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BGM Group	$37.92M	0.79	-$19.94M	N/A	N/A
ImmuCell	$27.64M	3.57	-$1.04M	-$0.06	N/A

BGM Group has a beta of 1.8, meaning that its stock price is 80% more volatile than the broader market. Comparatively, ImmuCell has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market.

13.5% of ImmuCell shares are owned by institutional investors. 58.7% of BGM Group shares are owned by company insiders. Comparatively, 5.7% of ImmuCell shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, ImmuCell had 4 more articles in the media than BGM Group. MarketBeat recorded 4 mentions for ImmuCell and 0 mentions for BGM Group. BGM Group's average media sentiment score of 0.00 equaled ImmuCell'saverage media sentiment score.

Company	Overall Sentiment
BGM Group	Neutral
ImmuCell	Neutral

BGM Group has a net margin of 0.00% compared to ImmuCell's net margin of -1.82%. BGM Group's return on equity of 0.00% beat ImmuCell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BGM Group	N/A	N/A	N/A
ImmuCell	-1.82%	-1.88%	-1.22%

Summary

BGM Group beats ImmuCell on 6 of the 10 factors compared between the two stocks.

How does BGM Group compare to Heron Therapeutics?

Heron Therapeutics (NASDAQ:HRTX) and BGM Group (NASDAQ:BGM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

BGM Group has lower revenue, but higher earnings than Heron Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heron Therapeutics	$150.71M	0.47	-$20.19M	-$0.18	N/A
BGM Group	$37.92M	0.79	-$19.94M	N/A	N/A

Heron Therapeutics presently has a consensus target price of $2.00, suggesting a potential upside of 439.08%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Heron Therapeutics is more favorable than BGM Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heron Therapeutics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Heron Therapeutics has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market. Comparatively, BGM Group has a beta of 1.8, meaning that its stock price is 80% more volatile than the broader market.

80.0% of Heron Therapeutics shares are owned by institutional investors. 6.1% of Heron Therapeutics shares are owned by insiders. Comparatively, 58.7% of BGM Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Heron Therapeutics had 9 more articles in the media than BGM Group. MarketBeat recorded 9 mentions for Heron Therapeutics and 0 mentions for BGM Group. Heron Therapeutics' average media sentiment score of 0.78 beat BGM Group's score of 0.00 indicating that Heron Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Heron Therapeutics	Positive
BGM Group	Neutral

BGM Group has a net margin of 0.00% compared to Heron Therapeutics' net margin of -20.53%. BGM Group's return on equity of 0.00% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%
BGM Group	N/A	N/A	N/A

Summary

Heron Therapeutics and BGM Group tied by winning 7 of the 14 factors compared between the two stocks.

Get BGM Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BGM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BGM vs. The Competition

Export

Metric	BGM Group	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$29.94M	$11.91B	$7.03B	$12.96B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	N/A	788.49	269.93	24.86
Price / Sales	0.79	968.58	650.62	108.28
Price / Cash	N/A	15.12	28.89	37.44
Price / Book	0.08	10.34	11.25	6.44
Net Income	-$19.94M	$2.77B	$3.45B	$347.39M
7 Day Performance	5.84%	2.18%	3.67%	2.69%
1 Month Performance	-8.06%	-1.35%	-0.49%	-0.90%
1 Year Performance	-96.00%	191.22%	77.44%	23.51%

BGM Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BGM BGM Group	0.4578 of 5 stars	$0.31 +2.5%	N/A	-96.1%	$29.94M	$37.92M	N/A	298
PLYX Polaryx Therapeutics	3.2988 of 5 stars	$2.23 +1.8%	$8.50 +281.2%	N/A	$111.16M	N/A	N/A	11
CPIX Cumberland Pharmaceuticals	0.3771 of 5 stars	$7.80 +8.6%	N/A	+141.5%	$107.58M	$44.52M	N/A	80	Earnings Report
RFL Rafael	0.2625 of 5 stars	$1.90 -4.8%	N/A	+26.7%	$104M	$920K	N/A	20	Gap Up
ICCC ImmuCell	0.8936 of 5 stars	$11.07 +0.3%	N/A	+65.2%	$99.88M	$27.64M	N/A	70	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BGM) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BGM Group (BGM) Competitors

BGM vs. PLYX, CPIX, RFL, ICCC, and HRTX

How does BGM Group compare to Polaryx Therapeutics?

Summary

How does BGM Group compare to Cumberland Pharmaceuticals?

Summary

How does BGM Group compare to Rafael?

Summary

How does BGM Group compare to ImmuCell?

Summary

How does BGM Group compare to Heron Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGM vs. The Competition

BGM Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BGM Group (BGM) Competitors

BGM vs. PLYX, CPIX, RFL, ICCC, and HRTX

How does BGM Group compare to Polaryx Therapeutics?

Which has higher earnings and valuation, BGM or PLYX?

Is BGM or PLYX more profitable?

Does the media refer more to BGM or PLYX?

Do analysts prefer BGM or PLYX?

Summary

How does BGM Group compare to Cumberland Pharmaceuticals?

Do analysts prefer CPIX or BGM?

Is CPIX or BGM more profitable?

Does the media prefer CPIX or BGM?

Which has preferable valuation and earnings, CPIX or BGM?

Do institutionals and insiders have more ownership in CPIX or BGM?

Which has more risk & volatility, CPIX or BGM?

Summary

How does BGM Group compare to Rafael?

Does the media prefer RFL or BGM?

Is RFL or BGM more profitable?

Which has better earnings & valuation, RFL or BGM?

Do institutionals & insiders hold more shares of RFL or BGM?

Do analysts rate RFL or BGM?

Which has more volatility & risk, RFL or BGM?

Summary

How does BGM Group compare to ImmuCell?

Which has higher earnings and valuation, BGM or ICCC?

Which has more volatility & risk, BGM or ICCC?

Do insiders and institutionals believe in BGM or ICCC?

Do analysts recommend BGM or ICCC?

Does the media refer more to BGM or ICCC?

Is BGM or ICCC more profitable?

Summary

How does BGM Group compare to Heron Therapeutics?

Which has preferable valuation & earnings, HRTX or BGM?

Do analysts prefer HRTX or BGM?

Which has more volatility and risk, HRTX or BGM?

Do insiders & institutionals have more ownership in HRTX or BGM?

Does the media prefer HRTX or BGM?

Is HRTX or BGM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGM vs. The Competition

BGM Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools